10-K: Bio-Techne Announces Merger with Merck KGaA

Bio-Techne Corporation has entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany, for $73.00 per share in cash, with an expected closing by late 2026 or early 2027.

Summary

• Bio-Techne Corporation has agreed to be acquired by Merck KGaA, Darmstadt, Germany, for $73.00 per share in cash, representing a significant premium.
• The merger is expected to close by late 2026 or early 2027, subject to customary closing conditions, including shareholder and regulatory approvals.
• For the fiscal year ended June 30, 2026, consolidated net sales remained flat at $1.2 billion, with organic revenue also flat year-over-year.
• Consolidated net earnings for fiscal 2026 increased significantly due to prior year charges, but adjusted net earnings decreased by 1% due to unfavorable product mix and pricing pressures.
• The company's Protein Sciences segment saw a 1% increase in net sales, while the Diagnostics and Spatial Biology segment experienced a 3% decrease.
• The company maintains a strong liquidity position with $264.7 million in cash, cash equivalents, and available-for-sale investments as of June 30, 2026.
• The company's insider trading policy and blackout periods are detailed, emphasizing compliance and responsible trading practices for employees and executives.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as generally positive, primarily due to the pending acquisition by Merck KGaA at a premium, despite mixed operational results.

Positives

• Agreement to be acquired by Merck KGaA, Darmstadt, Germany, for $73.00 per share in cash, providing a significant premium to shareholders.
• Strong liquidity position with $264.7 million in cash, cash equivalents, and available-for-sale investments as of June 30, 2026.
• The company's Protein Sciences segment continues to be a strong performer, with net sales increasing 1% in fiscal 2026.
• The company has a robust intellectual property portfolio with approximately 487 granted patents and 230 pending applications.
• Effective internal control over financial reporting as of June 30, 2026, as confirmed by independent auditors.

Negatives

• Consolidated net sales remained flat at $1.2 billion for fiscal year 2026.
• Adjusted net earnings decreased by 1% in fiscal 2026 compared to fiscal 2025, primarily due to unfavorable product mix and pricing pressures.
• The Diagnostics and Spatial Biology segment experienced a 3% decrease in net sales in fiscal 2026.
• Gross margins for the Protein Sciences segment decreased slightly in fiscal 2026 compared to fiscal 2025 due to unfavorable product mix and pricing pressures.
• Selling, general, and administrative expenses increased significantly in fiscal 2025 compared to fiscal 2024 due to non-recurring charges.

Risks

• The merger may not be completed in a timely manner or at all, due to failure to satisfy closing conditions, including regulatory and shareholder approvals.
• The announcement and pendency of the merger could disrupt business relationships with customers, suppliers, distributors, and employees.
• Diversion of management's attention from ongoing business operations due to merger-related activities.
• Potential for shareholder litigation or other legal proceedings related to the merger.
• Restrictions imposed by the merger agreement could affect the company's ability to execute business strategies or pursue other opportunities.
• Employee retention and recruitment may be challenging due to uncertainty surrounding future roles and employment following the merger.
• The company is subject to extensive government regulations in the life sciences and diagnostics industries, with potential for adverse effects from changes in these regulations.
• Cybersecurity threats and data breaches could result in significant damage to reputation, data integrity, and subject the company to costs, fines, or lawsuits.

Future Outlook

The company's future is largely defined by the pending acquisition by Merck KGaA, Darmstadt, Germany, expected to close by late 2026 or early 2027. Operationally, the company aims to continue growing its core business and capitalizing on high-potential markets through innovation and strategic acquisitions, while delivering best-in-class customer experience and developing its people.

Management Comments

• The company is committed to providing the life sciences community with innovative, high-quality scientific tools that allow customers to make extraordinary discoveries and treat and diagnose diseases.
• The company intends to build on its past accomplishments, high product quality reputation, and sound financial position by executing strategies that position it to serve as the standard for biological content in the research market and leverage that leadership position to enter the diagnostics and other adjacent markets.
• The company is intentionally fostering an EPIC culture based on the ideals of Empowerment, Passion, Innovation and Collaboration to effectively implement its global strategies.

Industry Context

StockSavvy.ai notes that Bio-Techne operates in the highly competitive life sciences and diagnostics markets, which are characterized by rapid technological change and consolidation. The pending acquisition by Merck KGaA, a major global player in the healthcare and life sciences sectors, signals a trend of consolidation and strategic investment within the industry.

Legal Proceedings

• As of August 24, 2026, the Company is not a party to any legal proceedings that, individually or in the aggregate, are reasonably expected to have a material adverse effect on the Company's business, results of operations, financial condition or cash flows.

Stakeholder Impact

• Shareholders are expected to benefit from the acquisition by Merck KGaA at a premium price of $73.00 per share.
• Employees may experience uncertainty regarding their future roles and employment following the merger, although retention arrangements are in place for executive officers.
• Customers, suppliers, and distributors may experience disruptions or changes in business relationships due to the pendency of the merger.
• Creditors' positions are not explicitly detailed in relation to the merger, but the company's credit facility remains in place.

Next Steps

• Complete the merger with Merck KGaA, Darmstadt, Germany, subject to shareholder and regulatory approvals.
• Continue to execute strategies to grow and leverage the core business.
• Capitalize on high-potential markets through innovation and acquisition.
• Expand product offerings into novel research fields and further penetrate diagnostics and therapeutics markets.
• Deliver best-in-class customer experience by expanding sales staff and distribution channels globally.
• Develop people through a transformative culture based on EPIC values.

Key Dates

Recommendation

The pending acquisition at a premium provides a clear exit for shareholders, making a 'hold' recommendation appropriate. While operational performance has been mixed, the certainty of the acquisition price outweighs the near-term operational risks. Investors should monitor the closing conditions and regulatory approvals.

Keywords

Bio-Techne, Merger, Life Sciences, Diagnostics, Spatial Biology, Protein Sciences, NASDAQ:TECH, Merck KGaA